Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) FCF Margin (2016 - 2025)

Historic FCF Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 32.56%.

  • Theravance Biopharma's FCF Margin fell 16600.0% to 32.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 303.15%, marking a year-over-year increase of 3226300.0%. This contributed to the annual value of 18.43% for FY2024, which is 329100.0% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's FCF Margin is 32.56%, which was down 16600.0% from 794.33% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's FCF Margin ranged from a high of 794.33% in Q2 2025 and a low of 1077.36% during Q1 2022
  • In the last 5 years, Theravance Biopharma's FCF Margin had a median value of 96.65% in 2023 and averaged 170.75%.
  • Its FCF Margin has fluctuated over the past 5 years, first surged by 32345700bps in 2021, then plummeted by -5749300bps in 2022.
  • Over the past 5 years, Theravance Biopharma's FCF Margin (Quarter) stood at 305.73% in 2021, then plummeted by -178bps to 848.67% in 2022, then skyrocketed by 99bps to 8.72% in 2023, then soared by 33bps to 5.82% in 2024, then crashed by -459bps to 32.56% in 2025.
  • Its FCF Margin was 32.56% in Q3 2025, compared to 794.33% in Q2 2025 and 279.69% in Q1 2025.